3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine - PubMed (original) (raw)

Comparative Study

3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine

D J McKenna et al. Pharmacol Biochem Behav. 1991 Mar.

Free article

Abstract

The effect of various analogues of the neurotoxic amphetamine derivative, MDA (3,4-methylenedioxyamphetamine) on carrier-mediated, calcium-independent release of 3H-5-HT and 3H-DA from rat brain synaptosomes was investigated. Both enantiomers of the neurotoxic analogues MDA and MDMA (3,4-methylenedioxymethamphetamine) induce synaptosomal release of 3H-5-HT and 3H-DA in vitro. The release of 3H-5-HT induced by MDMA is partially blocked by 10(-6) M fluoxetine. The (+) enantiomers of both MDA and MDMA are more potent than the (-) enantiomers as releasers of both 3H-5-HT and 3H-DA. Eleven analogues, differing from MDA with respect to the nature and number of ring and/or side chain substituents, also show some activity in the release experiments, and are more potent as releasers of 3H-5-HT than of 3H-DA. The amphetamine derivatives (+/-)fenfluramine, (+/-)norfenfluramine, (+/-)MDE, (+/-)PCA, and d-methamphetamine are all potent releasers of 3H-5-HT and show varying degrees of activity as 3H-DA releasers. The hallucinogen DOM does not cause significant release of either 3H-monoamine. Possible long-term serotonergic neurotoxicity was assessed by quantifying the density of 5-HT uptake sites in rats treated with multiple doses of selected analogues using 3H-paroxetine to label 5-HT uptake sites. In the neurotoxicity study of the compounds investigated, only (+)MDA caused a significant loss of 5-HT uptake sites in comparison to saline-treated controls. These results are discussed in terms of the apparent structure-activity properties affecting 3H-monoamine release and their possible relevance to neurotoxicity in this series of MDA congeners.

PubMed Disclaimer

Cited by

The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, Colado MI. Sanchez V, et al. Br J Pharmacol. 2001 Sep;134(1):46-57. doi: 10.1038/sj.bjp.0704230. Br J Pharmacol. 2001. PMID: 11522596 Free PMC article.
Can research on entactogens contribute to a deeper understanding of human sexuality?
Holka-Pokorska J. Holka-Pokorska J. Pharmacol Rep. 2023 Dec;75(6):1381-1397. doi: 10.1007/s43440-023-00552-7. Epub 2023 Nov 8. Pharmacol Rep. 2023. PMID: 37935915 Free PMC article. Review.
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
Colado MI, Williams JL, Green AR. Colado MI, et al. Br J Pharmacol. 1995 Aug;115(7):1281-9. doi: 10.1111/j.1476-5381.1995.tb15037.x. Br J Pharmacol. 1995. PMID: 7582557 Free PMC article.
Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.
Hegadoren KM, Martin-Iverson MT, Baker GB. Hegadoren KM, et al. Psychopharmacology (Berl). 1995 Apr;118(3):295-304. doi: 10.1007/BF02245958. Psychopharmacology (Berl). 1995. PMID: 7617822
Role of mucosal dendritic cells in inflammatory bowel disease.
Niess JH. Niess JH. World J Gastroenterol. 2008 Sep 7;14(33):5138-48. doi: 10.3748/wjg.14.5138. World J Gastroenterol. 2008. PMID: 18777590 Free PMC article. Review.

3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine - PubMed (original) (raw)